4//SEC Filing
KASINGER JAMES R. 4
Accession 0001193125-25-240437
CIK 0001674416other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 5:35 PM ET
Size
9.0 KB
Accession
0001193125-25-240437
Insider Transaction Report
Form 4
KASINGER JAMES R.
General Counsel and Secretary
Transactions
- Sale
Common Shares
2025-10-14$66.60/sh−1,076$71,662→ 83,402 total - Exercise/Conversion
Common Shares
2025-10-13+2,114→ 84,478 total - Exercise/Conversion
Restricted Stock Units
2025-10-13−2,114→ 2,113 total→ Common Shares (2,114 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
- [F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F4]This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001708172
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 5:35 PM ET
- Size
- 9.0 KB